<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229176</url>
  </required_header>
  <id_info>
    <org_study_id>H01_02TP</org_study_id>
    <nct_id>NCT01229176</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants</brief_title>
  <official_title>A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the
      Vi-CRM197 in subjects from various age groups in India and Pakistan where Typhoid Fever is
      highly endemic and an efficacious vaccine against this disease is very much needed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer</measure>
    <time_frame>At 28 days after last vaccination as compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer</measure>
    <time_frame>At 6 months after last vaccination as compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Vi ELISA Geometric Mean Concentration (GMC)</measure>
    <time_frame>At 28 days after last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Vi ELISA GMC</measure>
    <time_frame>At 6 months after last vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Solicited Local and Systemic Reaction, After Any Vaccination</measure>
    <time_frame>During the 7-day follow-up period after vaccination</time_frame>
    <description>Solicited local reactions were: Adults, children, older infants, infants: erythema, induration and pain/tenderness at the injection site.
Solicited systemic reactions were: Adults: chills, malaise, myalgia, arthralgia, headache, fatigue, rash and fever.
Children, older infants and infants: lethargy, irritability, vomiting, diarrhoea, loss of appetite, rash and fever (and persistent crying in infants).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Vi-CRM, Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-PS, Adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-CRM, Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-PS, Children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-CRM, Older infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNC13, Older infants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-CRM, Infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNC13, Infants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi-CRM197 vaccine</intervention_name>
    <arm_group_label>Vi-CRM, Adults</arm_group_label>
    <arm_group_label>Vi-CRM, Children</arm_group_label>
    <arm_group_label>Vi-CRM, Older infants</arm_group_label>
    <arm_group_label>Vi-CRM, Infants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi Polysaccharide (PS) vaccine</intervention_name>
    <arm_group_label>Vi-PS, Adults</arm_group_label>
    <arm_group_label>Vi-PS, Children</arm_group_label>
    <other_name>Typherix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine</intervention_name>
    <arm_group_label>Vi-PS, Children</arm_group_label>
    <arm_group_label>PNC13, Older infants</arm_group_label>
    <arm_group_label>PNC13, Infants</arm_group_label>
    <other_name>Prevenar 13</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main eligibility criteria:

          -  Subjects belonging to 4 age groups will be enrolled into the trial: adults (18 to 45
             years of age), children (24 to 59 months of age), older infants (9 to 12 months of age
             at enrollment) and infants (6 weeks of age at enrolment).

          -  Written informed consent will be obtained by the all subjects or their parents/
             guardians (depending on the age group) before enrollment into the trial.

          -  Only females with a negative pregnancy test and willing to participate in family
             planning consultations (organized by the site study team) will be allowed to
             participate to the trial.

          -  Infants who have been vaccinated with 1 dose of BCG, HBV and OPV at birth can be
             enrolled into the trial, while infants who have received DTwP+HBV+Hib or OPV due at 6
             weeks of age as per local EPI schedule cannot be enrolled into the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NVGH</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>K.E.M. Hospital Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharastra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aga Khan University Hospital</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Pakistan</country>
  </location_countries>
  <results_reference>
    <citation>Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014 Feb;14(2):119-29. doi: 10.1016/S1473-3099(13)70241-X. Epub 2013 Nov 28.</citation>
    <PMID>24290843</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <results_first_submitted>March 5, 2014</results_first_submitted>
  <results_first_submitted_qc>March 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2014</results_first_posted>
  <last_update_submitted>April 11, 2014</last_update_submitted>
  <last_update_submitted_qc>April 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vi-CRM, Adults</title>
          <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="P2">
          <title>Vi-PS, Adults</title>
          <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
        </group>
        <group group_id="P3">
          <title>Vi-CRM, Children</title>
          <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="P4">
          <title>Vi-PS, Children</title>
          <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="P5">
          <title>Vi-CRM, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="P6">
          <title>PNC13, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="P7">
          <title>Vi-CRM, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="P8">
          <title>PNC13, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled Set</population>
      <group_list>
        <group group_id="B1">
          <title>Vi-CRM, Adults</title>
          <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="B2">
          <title>Vi-PS, Adults</title>
          <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
        </group>
        <group group_id="B3">
          <title>Vi-CRM, Children</title>
          <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="B4">
          <title>Vi-PS, Children</title>
          <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="B5">
          <title>Vi-CRM, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="B6">
          <title>PNC13, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="B7">
          <title>Vi-CRM, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="B8">
          <title>PNC13, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="20"/>
            <count group_id="B8" value="20"/>
            <count group_id="B9" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 weeks to 8 weeks (infants)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months to 12 months (older infants)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months 59 months (children)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 years to 45 years (adults)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pakistan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer</title>
        <time_frame>At 28 days after last vaccination as compared to baseline</time_frame>
        <population>Intention-to-treat analysis set, which included all participants who received the vaccination, those in whom at least one post-vaccination blood sample was collected, and those for whom at least one ELISA result was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O7">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O8">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer</title>
          <population>Intention-to-treat analysis set, which included all participants who received the vaccination, those in whom at least one post-vaccination blood sample was collected, and those for whom at least one ELISA result was available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="85" lower_limit="70" upper_limit="94"/>
                    <measurement group_id="O3" value="100" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O4" value="89" lower_limit="67" upper_limit="99"/>
                    <measurement group_id="O5" value="95" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O7" value="85" lower_limit="62" upper_limit="97"/>
                    <measurement group_id="O8" value="6" lower_limit="0" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer</title>
        <time_frame>At 6 months after last vaccination as compared to baseline</time_frame>
        <population>Intention-to-treat analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O7">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O8">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer</title>
          <population>Intention-to-treat analysis set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="76" upper_limit="97"/>
                    <measurement group_id="O2" value="81" lower_limit="65" upper_limit="92"/>
                    <measurement group_id="O3" value="95" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O4" value="68" lower_limit="43" upper_limit="87"/>
                    <measurement group_id="O5" value="89" lower_limit="65" upper_limit="99"/>
                    <measurement group_id="O6" value="6" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O7" value="25" lower_limit="9" upper_limit="49"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Vi ELISA Geometric Mean Concentration (GMC)</title>
        <time_frame>At 28 days after last vaccination</time_frame>
        <population>Intention-to-treat analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O7">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O8">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Vi ELISA Geometric Mean Concentration (GMC)</title>
          <population>Intention-to-treat analysis set</population>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" lower_limit="105" upper_limit="224"/>
                    <measurement group_id="O2" value="44" lower_limit="30" upper_limit="65"/>
                    <measurement group_id="O3" value="136" lower_limit="91" upper_limit="202"/>
                    <measurement group_id="O4" value="53" lower_limit="36" upper_limit="79"/>
                    <measurement group_id="O5" value="109" lower_limit="80" upper_limit="148"/>
                    <measurement group_id="O6" value="1.43" lower_limit="1.03" upper_limit="2"/>
                    <measurement group_id="O7" value="23" lower_limit="17" upper_limit="32"/>
                    <measurement group_id="O8" value="2.33" lower_limit="1.63" upper_limit="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Vi ELISA GMC</title>
        <time_frame>At 6 months after last vaccination</time_frame>
        <population>Intention-to-treat analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O7">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O8">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Vi ELISA GMC</title>
          <population>Intention-to-treat analysis set</population>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="40" upper_limit="87"/>
                    <measurement group_id="O2" value="36" lower_limit="24" upper_limit="53"/>
                    <measurement group_id="O3" value="23" lower_limit="15" upper_limit="34"/>
                    <measurement group_id="O4" value="25" lower_limit="17" upper_limit="38"/>
                    <measurement group_id="O5" value="22" lower_limit="14" upper_limit="33"/>
                    <measurement group_id="O6" value="3.12" lower_limit="2.08" upper_limit="4.68"/>
                    <measurement group_id="O7" value="3.76" lower_limit="2.77" upper_limit="5.08"/>
                    <measurement group_id="O8" value="1.41" lower_limit="1.02" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Solicited Local and Systemic Reaction, After Any Vaccination</title>
        <description>Solicited local reactions were: Adults, children, older infants, infants: erythema, induration and pain/tenderness at the injection site.
Solicited systemic reactions were: Adults: chills, malaise, myalgia, arthralgia, headache, fatigue, rash and fever.
Children, older infants and infants: lethargy, irritability, vomiting, diarrhoea, loss of appetite, rash and fever (and persistent crying in infants).</description>
        <time_frame>During the 7-day follow-up period after vaccination</time_frame>
        <population>Analysis was done on as treated safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Adults</title>
            <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O7">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O8">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Solicited Local and Systemic Reaction, After Any Vaccination</title>
          <description>Solicited local reactions were: Adults, children, older infants, infants: erythema, induration and pain/tenderness at the injection site.
Solicited systemic reactions were: Adults: chills, malaise, myalgia, arthralgia, headache, fatigue, rash and fever.
Children, older infants and infants: lethargy, irritability, vomiting, diarrhoea, loss of appetite, rash and fever (and persistent crying in infants).</description>
          <population>Analysis was done on as treated safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited Adverse Events (AEs) were collected during 7-day follow period after each vaccination. Serious AEs were collected throughout the study period. Unsolicited AEs were collected collected during 28-day follow period after each vaccination.</time_frame>
      <desc>Analysis was done on as treated safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>Vi-CRM, Adults</title>
          <description>Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="E2">
          <title>Vi-PS, Adults</title>
          <description>Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine</description>
        </group>
        <group group_id="E3">
          <title>Vi-CRM, Children</title>
          <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="E4">
          <title>Vi-PS, Children</title>
          <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="E5">
          <title>Vi-CRM, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="E6">
          <title>PNC13, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="E7">
          <title>Vi-CRM, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="E8">
          <title>PNC13, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for children, older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pian</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pian</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for children, older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for children, older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for adults</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for adults</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for children, older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for adults</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for adults</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for adults</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for adults</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for children, older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating Disorder</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>systemic assessment for children, older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Heat Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event that no publication of the Study results has been made by NVGH within twelve (12) months of Study database lock and no proposed publication is under discussion by the publication committee, Principal Investigator may publish its own Study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Audino Podda</name_or_title>
      <organization>Novartis Vaccines Institute for Global Health</organization>
      <phone>+39 0577 243496</phone>
      <email>audino.podda@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

